Kodu・Aktsiate loetelu・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Avatud

SektorTervishoid

39.07 4.27

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

37.29

Max

39.07

Põhinäitajad
By Trading Economics
Sissetulek	2.6M -79M
Müük	-60K 15K
Aktsiakasum	-1.18
Kasumimarginaal	-524,566.667
Töötajad	198
EBITDA	2.7M -78M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+51.02% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	226M 2.8B
Eelmine avamishind	34.8
Eelmine sulgemishind	39.07

Uudiste sentiment

By Acuity

50%

151 / 340 Pingereas Healthcare

Celldex Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. aug 2026, 19:53 UTC

Celldex Therapeutics Inc. shares are lower as biotechnology stocks decline. The broader sector's weakness has influenced the stock's price action today.

31. juuli 2026, 19:36 UTC

Celldex Therapeutics Inc. shares are lower today amid significant pressure on biotechnology stocks, with no specific company news identified to explain the decline.

30. juuli 2026, 18:51 UTC

Celldex Therapeutics Inc is advancing during Thursday's session, moving higher alongside the broader market amid positive macroeconomic sentiment.

29. juuli 2026, 20:03 UTC

Macro Event

News

Wells Fargo raised its price target on Celldex Therapeutics to $72, citing confidence in the company's growth prospects and promising pipeline. Shares are higher today.

28. juuli 2026, 19:36 UTC

Shares of Celldex Therapeutics Inc. are lower today, continuing a decline since Monday's close, despite an earlier modest rebound from session lows.

27. juuli 2026, 19:31 UTC

News

Celldex Therapeutics is higher today, bolstered by strong sentiment for its barzolvolimab program and successful Phase 3 enrollment for chronic spontaneous urticaria trials.

22. juuli 2026, 20:01 UTC

Event

News

Social Media

Celldex Therapeutics is lower after discontinuing barzolvolimab development due to failed trial results. Wells Fargo lowered its price target to $48.

21. juuli 2026, 23:01 UTC

Social Media

Event

News

Celldex Therapeutics shares fell in after-market hours following disappointing Phase 2 trial results for barzolvolimab, which failed to meet primary and secondary endpoints.

Võrdlus sarnastega

Hinnamuutus

Celldex Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

51.02% tõus

12 kuu keskmine prognoos

Keskmine 56.92 USD 51.02%

Kõrge 100 USD

Madal 34 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Celldex Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Celldex Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

151 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.